2011, Number 25
PDF size: 122.52 Kb.
ABSTRACTKnowledge of the mechanisms of action of beta blockers in the sympathetic system has led to the controversial use of these in heart failure. In spite of their antagonistic effects on chronotropic and inotropic functions of the heart, they are now part of the treatment strategies endorsed by the FDA for heart failure. With the use of beta blockers, a decrease has been observed in pro-inflammatory agents as well as an inhibition of the vasoconstrictor neurohormonal system, the sympathetic system, in response to low output; if these factors are not controlled, heart failure can be perpetuated.
In recent years many clinical studies have been conducted mainly with the use of metoprolol, carvedilol and bisoprolol, with favorable results; increasing survival and decreasing the symptoms, number of hospitalizations and mortality in patients with heart failure. Our objective was to analyze the different studies on the use of beta blockers in heart failure.
Marco Metra, Savina Nodari “Beta- Blockers in Heart Failure: Are PharmacologicalDifferences Clinically Important?” Cattedra di Cardiologia, Universit `a di Brescia, Italy;Deptartment of Cardiology, Ospedale di Cattinara, Trieste, Italy; 3National Heart and Lung Institute, Imperial CollegeLondon, UK Heart Failure Reviews, 9, 2004;123:130,
Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.
Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.
Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295.